Posted by Michael Wonder on 21 Nov 2022
US FDA accepts for priority review the biologics license application for epcoritamab (DuoBody-CD3xCD20) for the treatment of relapsed/refractory large B-cell lymphoma
21 November 2022 - The application is supported by data from EPCORE NHL-1 Phase 1/2 trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20 positive, mature B-cell non-Hodgkin's lymphoma, including large B-cell lymphoma.
AbbVie today announced that the US FDA has accepted for priority review the Biologics License Application for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy.
